TG Therapeutics | TGTX - Cash And Equivalent



TG Therapeutics reported $278.86M in Cash and Equivalent for its fiscal quarter ending in June of 2025.


Cash And Equivalent Change Date
AbbVie USD 5.18B 349M Mar/2025
Alaunos Therapeutics USD 1.09M 592K Dec/2024
Amgen USD 8.03B 782M Jun/2025
Ardelyx USD 90.04M 41.39M Jun/2025
Arrowhead Research USD 129.79M 55.92M Jun/2025
Bayer EUR 4.56B 542M Jun/2025
Biogen USD 2.76B 160.5M Jun/2025
Corcept Therapeutics USD 102.74M 12.93M Jun/2025
Dynavax Technologies USD 99.1M 562.24M Jun/2025
Gilead Sciences USD 5.14B 2.78B Jun/2025
J&J USD 38.47B 32.35B Mar/2025
Novartis USD 6.66B 410M Jun/2025
PTC Therapeutics USD 1.02B 1.01B Jun/2025
Regeneron Pharmaceuticals USD 2B 1.09B Jun/2025
Roche Holding CHF 6.98B 2.15B Dec/2024
TG Therapeutics USD 278.86M 146.72M Jun/2025
Vertex Pharmaceuticals USD 6.38B 1.71B Jun/2025